Abstract:The present work describes the synthesis and docking of heterocyclically substituted glycinamide derivatives. These derivatives are assessed in vitro for DPP 4 inhibition. Compound 2‐(4‐fluorophenethylamino)‐1‐(4‐(6‐fluorobenzo[d]isoxazol‐3‐yl)piperidin‐1‐yl)ethan‐1‐one (JAG‐D2), showing promising results during in vitro assessment was evaluated in vivo using OGTT assay in streptozotocin‐induced diabetic rats. The structure‐activity relationship studies based the binding mode of glycinamide derivatives and MD simulation of JAG‐D2 are discussed. According to the International Diabetes Federation, the global prevalence of diabetes is projected to increase to 643 million individuals by 2030 and 783 million by 2045. DPP 4 inhibitors approved by regulatory authorities worldwide, efficiently to regulate high blood sugar levels by impeding the degradation of glucagon like peptide‐1 (GLP‐1), an incretin hormone, prolonging the physiological effects of GLP‐1. In the present research work, a total of 12 glycinamide‐based compounds with aromatic substituents on the N‐terminus and heterocycles like piperidine, 4‐phenylpiperazine, and 6‐fluorobenzo[d]isoxazol‐3‐piperidine on the C‐terminus were synthesized and characterized. The synthesized compounds were subjected to in vitro DPP 4 inhibition assay. The promising compound JAG‐D2 was evaluated in vivo using OGTT assay in streptozotocin‐induced diabetic rats. JAG‐D2 produced a significant reduction in blood glucose levels at 20 mg/kg and 40 mg/kg doses when compared with a 1 mg/kg dose of the reference standard sitagliptin. The synthesized compounds occupied the active site of DPP 4 as demonstrated in molecular docking and MM‐GBSA analysis for rescoring on the basis of binding free energy. Molecular dynamics studies displayed the stability of the docked pose of JAG‐D2 in the catalytic site of DPP 4. All compounds exhibited compliance with Lipinski's rule of five, suggesting drug‐like properties.

Current trends and future directions for the synthesis and pharmacological applications of 2-(2-cyanopyrrolidin-1-yl)-N-3-hydroxyadamantan-1-yl) acetamide (Gliptins)

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Synthesis and Evaluation of Antidiabetic Potential of Gliptin‐based Hybrid Scaffolds

Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents

Novel DPP-4 Inhibitors Against Diabetes

Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes

Computational Simulation Studies, Synthesis, In Vitro, and In Vivo Evaluation of Heterocyclically Substituted Glycinamide Derivatives as DPP 4 Inhibitors

Recent advances in peptidomimetic dipeptidyl peptidase Ⅳ inhibitors

Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: Past, present, and future

Stereochemical insights into β-amino-N-acylhydrazones and their impact on DPP-4 inhibition

Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids

Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors

A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues

Recent Developments in 1,2,3-Triazole Based α-Glucosidase Inhibitors: Design Strategies, Structure-Activity Relationship and Mechanistic Insights

Synthesis and Biological Evaluation of Pyrrolidine-2-carbonitrile and 4-Fluoropyrrolidine-2-carbonitrile Derivatives As Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes.

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay Between the N-terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of Alpha-Aminoacyl-l-cis-4,5-methanoprolinenitrile-based Inhibitors.

Recent advances and structure-activity relationship studies of DPP-4 inhibitors as anti-diabetic agents